These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7907248)

  • 21. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
    Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
    Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
    Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
    Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibodies to adhesion molecules inhibit the lytic function of MHC-unrestricted cytotoxic cells by preventing their activation.
    Zarcone D; Viale O; Cerruti G; Tenca C; Malorni W; Arancia G; Iosi F; Galandrini R; Velardi A; Moretta A
    Cell Immunol; 1992 Sep; 143(2):389-404. PubMed ID: 1380897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
    Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
    Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission.
    Adler A; Albo V; Blatt J; Whiteside TL; Herberman RB
    Blood; 1989 Oct; 74(5):1690-7. PubMed ID: 2790193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokine-activated killer cells: chemical specificity of target cell recognition.
    Mueller EA; Anderer FA
    Cancer Res; 1990 Jun; 50(12):3646-51. PubMed ID: 1692765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modulation of leukemic cell sensitivity to lymphokine-activated killer cytolysis: role of intercellular adhesion molecule-1.
    Triozzi PL; Eicher DM; Smoot J; Rinehart JJ
    Exp Hematol; 1992 Oct; 20(9):1072-6. PubMed ID: 1361453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH; Lydyard PM
    Leuk Lymphoma; 1992 Aug; 7(5-6):473-80. PubMed ID: 1362916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia.
    Verfaillie C; Kay N; Miller W; McGlave P
    Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of recombinant interleukin-2 administration on cytotoxic function following high-dose chemo-radiotherapy for hematological malignancy.
    Gottlieb DJ; Prentice HG; Heslop HE; Bello-Fernandez C; Bianchi AC; Galazka AR; Brenner MK
    Blood; 1989 Nov; 74(7):2335-42. PubMed ID: 2804369
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blocking of MHC class I antigens on leukemic B-cells enhances their conjugate formation with cytotoxic lymphocytes and their susceptibility to lysis.
    Palucka KA; Reizenstein P; Ost A; Porwit-MacDonald A
    Leuk Lymphoma; 1998 Feb; 28(5-6):573-81. PubMed ID: 9613988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells.
    Wallgren A; Festin R; Gidlöf C; Dohlsten M; Kalland T; Tötterman TH
    Blood; 1993 Aug; 82(4):1230-8. PubMed ID: 8102559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
    Donskov F; Basse PH; Hokland M
    Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Signal transduction via phosphorylated adhesion molecule, LFA-1 beta (CD18), is increased by culture of natural killer cells with IL-2 in the generation of lymphokine-activated killer cells.
    Umehara H; Takashima A; Minami Y; Bloom ET
    Int Immunol; 1993 Jan; 5(1):19-27. PubMed ID: 8095153
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of effector-target conjugates for cloned human natural killer and human lymphokine activated killer cells by flow cytometry.
    Callewaert DM; Radcliff G; Waite R; LeFevre J; Poulik MD
    Cytometry; 1991; 12(7):666-76. PubMed ID: 1782834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis.
    Robertson MJ; Caligiuri MA; Manley TJ; Levine H; Ritz J
    J Immunol; 1990 Nov; 145(10):3194-201. PubMed ID: 1700001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phorbol 12-myristate 13-acetate induces resistance of human melanoma cells to natural-killer- and lymphokine-activated-killer-mediated cytotoxicity.
    Correale P; Procopio A; Celio L; Caraglia M; Genua G; Coppola V; Pepe S; Normanno N; Vecchio I; Palmieri G
    Cancer Immunol Immunother; 1992; 34(4):272-8. PubMed ID: 1371427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
    Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
    Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.